347 related articles for article (PubMed ID: 9572884)
1. Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors.
Martin SF; Dorsey GO; Gane T; Hillier MC; Kessler H; Baur M; Mathä B; Erickson JW; Bhat TN; Munshi S; Gulnik SV; Topol IA
J Med Chem; 1998 May; 41(10):1581-97. PubMed ID: 9572884
[TBL] [Abstract][Full Text] [Related]
2. Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluation.
Ghosh AK; Kincaid JF; Walters DE; Chen Y; Chaudhuri NC; Thompson WJ; Culberson C; Fitzgerald PM; Lee HY; McKee SP; Munson PM; Duong TT; Darke PL; Zugay JA; Schleif WA; Axel MG; Lin J; Huff JR
J Med Chem; 1996 Aug; 39(17):3278-90. PubMed ID: 8765511
[TBL] [Abstract][Full Text] [Related]
3. 1,2,3-trisubstituted cyclopropanes as conformationally restricted peptide isosteres: application to the design and synthesis of novel renin inhibitors.
Martin SF; Austin RE; Oalmann CJ; Baker WR; Condon SL; deLara E; Rosenberg SH; Spina KP; Stein HH; Cohen J
J Med Chem; 1992 May; 35(10):1710-21. PubMed ID: 1588553
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and properties of cyclopropane-derived peptidomimetics.
Reichelt A; Martin SF
Acc Chem Res; 2006 Jul; 39(7):433-42. PubMed ID: 16846207
[TBL] [Abstract][Full Text] [Related]
6. Mapping hydration water molecules in the HIV-1 protease/DMP323 complex in solution by NMR spectroscopy.
Wang YX; Freedberg DI; Grzesiek S; Torchia DA; Wingfield PT; Kaufman JD; Stahl SJ; Chang CH; Hodge CN
Biochemistry; 1996 Oct; 35(39):12694-704. PubMed ID: 8841113
[TBL] [Abstract][Full Text] [Related]
7. New active HIV-1 protease inhibitors derived from 3-hexanol: conformation study of the free inhibitors in crystalline state and in complex with the enzyme.
Ziółkowska NE; Bujacz A; Randad RS; Erickson JW; Skálová T; Hašek J; Bujacz G
Chem Biol Drug Des; 2012 May; 79(5):798-809. PubMed ID: 22296826
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, and evaluation of tetrahydropyrimidinones as an example of a general approach to nonpeptide HIV protease inhibitors.
De Lucca GV; Liang J; Aldrich PE; Calabrese J; Cordova B; Klabe RM; Rayner MM; Chang CH
J Med Chem; 1997 May; 40(11):1707-9. PubMed ID: 9171880
[TBL] [Abstract][Full Text] [Related]
9. Inhibitor binding at the protein interface in crystals of a HIV-1 protease complex.
Brynda J; Rezácová P; Fábry M; Horejsí M; Stouracová R; Soucek M; Hradílek M; Konvalinka J; Sedlácek J
Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):1943-8. PubMed ID: 15502300
[TBL] [Abstract][Full Text] [Related]
10. Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease.
Specker E; Böttcher J; Brass S; Heine A; Lilie H; Schoop A; Müller G; Griebenow N; Klebe G
ChemMedChem; 2006 Jan; 1(1):106-17. PubMed ID: 16892342
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold.
Alterman M; Björsne M; Mühlman A; Classon B; Kvarnström I; Danielson H; Markgren PO; Nillroth U; Unge T; Hallberg A; Samuelsson B
J Med Chem; 1998 Sep; 41(20):3782-92. PubMed ID: 9748353
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements.
Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF
J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939
[TBL] [Abstract][Full Text] [Related]
13. Incorporating protein flexibility in structure-based drug discovery: using HIV-1 protease as a test case.
Meagher KL; Carlson HA
J Am Chem Soc; 2004 Oct; 126(41):13276-81. PubMed ID: 15479081
[TBL] [Abstract][Full Text] [Related]
14. Computational design of novel fullerene analogues as potential HIV-1 PR inhibitors: Analysis of the binding interactions between fullerene inhibitors and HIV-1 PR residues using 3D QSAR, molecular docking and molecular dynamics simulations.
Durdagi S; Mavromoustakos T; Chronakis N; Papadopoulos MG
Bioorg Med Chem; 2008 Dec; 16(23):9957-74. PubMed ID: 18996019
[TBL] [Abstract][Full Text] [Related]
15. Cyclopropane-derived peptidomimetics. design, synthesis, and evaluation of novel Ras farnesyltransferase inhibitors.
Hillier MC; Davidson JP; Martin SF
J Org Chem; 2001 Mar; 66(5):1657-71. PubMed ID: 11262110
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
[TBL] [Abstract][Full Text] [Related]
17. Molecular recognition of macrocyclic peptidomimetic inhibitors by HIV-1 protease.
Martin JL; Begun J; Schindeler A; Wickramasinghe WA; Alewood D; Alewood PF; Bergman DA; Brinkworth RI; Abbenante G; March DR; Reid RC; Fairlie DP
Biochemistry; 1999 Jun; 38(25):7978-88. PubMed ID: 10387041
[TBL] [Abstract][Full Text] [Related]
18. Potent HIV protease inhibitors containing a novel (hydroxyethyl)amide isostere.
Beaulieu PL; Wernic D; Abraham A; Anderson PC; Bogri T; Bousquet Y; Croteau G; Guse I; Lamarre D; Liard F; Paris W; Thibeault D; Pav S; Tong L
J Med Chem; 1997 Jul; 40(14):2164-76. PubMed ID: 9216835
[TBL] [Abstract][Full Text] [Related]
19. Countering cooperative effects in protease inhibitors using constrained beta-strand-mimicking templates in focused combinatorial libraries.
Reid RC; Pattenden LK; Tyndall JD; Martin JL; Walsh T; Fairlie DP
J Med Chem; 2004 Mar; 47(7):1641-51. PubMed ID: 15027855
[TBL] [Abstract][Full Text] [Related]
20. HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.
Skalova T; Dohnalek J; Duskova J; Petrokova H; Hradílek M; Soucek M; Konvalinka J; Hasek J
J Med Chem; 2006 Sep; 49(19):5777-84. PubMed ID: 16970402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
